Companies › Adicet Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADI-001 Anti-CD20 CAR-T cell therapy | CD20 | Phase 1 | Rheumatoid Arthritis (RA) | Mar 2027 |
| ADI-270 anti-CD70 CAR-T cell therapy (engineered gamma-delta Vδ1 T cells) | CD70 | Phase 1 | Clear Cell Renal Cell Carcinoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06480565 | ADI-270 | Phase 1 | Clear Cell Renal Cell Carcinoma | Oncology | Jul 2025 |
| NCT07100873 | ADI-001 | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Mar 2027 |
Cash of $27m on 2026-09-30; operating cash outflow about $79m a year; runway about 4 months at that burn, to Feb 2027
Press releases filed as 8-K in the last year:
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.